Pharmaceutical Investing Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
Pharmaceutical Investing Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
SOURCE ROCK ROYALTIES ANNOUNCES FOURTH QUARTER & YEAR-END 2024 RESULTS INCLUDING RECORD ANNUAL FUNDS FROM OPERATIONS
